Ascelia Pharma AB (OSTO:ACE) Other Long-Term Liabilities: kr-0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ACE Ascelia Pharma AB OSTO:ACE
22 GF Score
Price kr0.58
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Other Long-Term Liabilities?

Ascelia Pharma AB OSTO:ACE -0.86% 22 Other Long-Term Liabilities is kr-0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's other long-term liabilities for the quarter that ended in Mar. 2026 was kr-0.00 Mil.

Ascelia Pharma AB's quarterly other long-term liabilities increased from Sep. 2025 (kr-0.00 Mil) to Dec. 2025 (kr-0.00 Mil) but then declined from Dec. 2025 (kr-0.00 Mil) to Mar. 2026 (kr-0.00 Mil).

Ascelia Pharma AB's annual other long-term liabilities declined from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr0.00 Mil) and declined from Dec. 2024 (kr0.00 Mil) to Dec. 2025 (kr-0.00 Mil).

Ascelia Pharma AB Other Long-Term Liabilities Related Terms

Ascelia Pharma AB Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Other Long-Term Liabilities Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only -0.00 -0.00 0.00 0.00 -0.00

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 -0.00
OSTO:ACE
22GF Score
Ascelia Pharma AB OSTO:ACE
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of kr-0.00 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Other Long-Term Liabilities of kr-0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Other Long-Term Liabilities too high?
Ascelia Pharma AB's current Other Long-Term Liabilities is kr-0.00 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Other Long-Term Liabilities compare to VRTX and REGN?
Ascelia Pharma AB's Other Long-Term Liabilities of kr-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Other Long-Term Liabilities is kr-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Other Long-Term Liabilities of kr-0.00 Mil. The current Other Long-Term Liabilities is kr-0.00 Mil. Ascelia Pharma AB's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Other Long-Term Liabilities is kr-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
22GF Score

Get the complete analysis for OSTO:ACE

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.58
Price